DexCom (DXCM) Stock Forecast, Price & News

DexCom (NASDAQ:DXCM) Frequently Asked Questions

Is DexCom a buy right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 1 hold rating and 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DexCom stock.
View analyst ratings for DexCom or view top-rated stocks.

When is DexCom's next earnings date?

DexCom is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for DexCom.

How were DexCom's earnings last quarter?

DexCom, Inc. (NASDAQ:DXCM) released its quarterly earnings data on Thursday, April, 28th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.52 by $0.20. The medical device company had revenue of $628.80 million for the quarter, compared to analyst estimates of $623.97 million. DexCom had a trailing twelve-month return on equity of 12.42% and a net margin of 8.23%. The company's quarterly revenue was up 24.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.33 earnings per share.
View DexCom's earnings history.

When did DexCom's stock split? How did DexCom's stock split work?

DexCom shares split on the morning of Friday, June 10th 2022. The 4-1 split was announced on Friday, March 25th 2022. The newly minted shares will be distributed to shareholders after the closing bell on Thursday, June 9th 2022. An investor that had 100 shares of DexCom stock prior to the split would have 400 shares after the split.

What guidance has DexCom issued on next quarter's earnings?

DexCom updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.82 billion-$2.94 billion, compared to the consensus revenue estimate of $2.92 billion.

What price target have analysts set for DXCM?

15 Wall Street analysts have issued 1 year price targets for DexCom's stock. Their forecasts range from $480.00 to $655.00. On average, they expect DexCom's share price to reach $549.07 in the next year. This suggests a possible upside of 69.2% from the stock's current price.
View analysts' price targets for DexCom or view top-rated stocks among Wall Street analysts.

Who are DexCom's key executives?

DexCom's management team includes the following people:

• Mr. Kevin Ronald Sayer, Exec. Chairman, CEO & Pres (Age 64, Pay $2.39M)
• Mr. Jereme M. Sylvain, Exec. VP, CFO & Chief Accounting Officer (Age 42, Pay $783.16k) (LinkedIn Profile)
• Mr. Jacob Steven Leach, Exec. VP & CTO (Age 44, Pay $915.93k) (LinkedIn Profile)
• Mr. Chad M. Patterson, Exec. VP of Global Marketing (Age 40, Pay $770.49k) (LinkedIn Profile)
• Mr. Paul R. Flynn, Exec. VP of Global Revenue (Age 53, Pay $761.52k) (LinkedIn Profile)
• Mr. Barry J. Regan, Exec. VP of Global Operations (Age 49) (LinkedIn Profile)
• Mr. Shelly Ramasamy Selvaraj, Sr. VP & Chief Information Officer (Age 63)
• Mr. Sean Christensen, Director of Corp. Affairs & Head of Investor Relations
• Mr. Michael Brown, Exec. VP & Chief Legal Officer (Age 52)
• Mr. Matthew Dolan, Sr. VP of Strategy, Corp. Devel. & New Markets (Age 41)

What is Kevin Sayer's approval rating as DexCom's CEO?

347 employees have rated DexCom CEO Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among DexCom's employees.

Who are some of DexCom's key competitors?

Some companies that are related to DexCom include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), STERIS (STE), Hologic (HOLX), Insulet (PODD), Teleflex (TFX) and Abiomed (ABMD).
View all of DXCM's competitors.

What other stocks do shareholders of DexCom own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Salesforce (CRM), ServiceNow (NOW), Walt Disney (DIS), Trade Desk (TTD) and Shopify (SHOP).

What is DexCom's stock symbol?

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

Who are DexCom's major shareholders?

DexCom's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (10.75%), Baillie Gifford & Co. (4.64%), Sands Capital Management LLC (4.27%), Jennison Associates LLC (2.65%), Brown Advisory Inc. (1.37%) and Clearbridge Investments LLC (1.34%). Company insiders that own DexCom stock include Andrew K Balo, Andrew K Balo, Barbara Kahn, Barry J Regan, Bridgette P Heller, Chad Patterson, Jacob Steven Leach, Jay S Skyler, Jereme M Sylvain, Jereme M Sylvain, Kevin R Sayer, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Sadie Stern, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli and Sumi Shrishrimal.
View institutional ownership trends for DexCom.

Which major investors are selling DexCom stock?

DXCM stock was sold by a variety of institutional investors in the last quarter, including Pier 88 Investment Partners LLC, Gabelli Funds LLC, Zurcher Kantonalbank Zurich Cantonalbank , Compagnie Lombard Odier SCmA, Pallas Capital Advisors LLC, Lord Abbett & CO. LLC, Renaissance Technologies LLC, and 1832 Asset Management L.P.. Company insiders that have sold DexCom company stock in the last year include Andrew K Balo, Barbara Kahn, Barry J Regan, Chad Patterson, Jacob Steven Leach, Jay S Skyler, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Alexander Collins, Sadie Stern, Shelly Ramasamy Selvaraj, Steven Robert Pacelli, and Sumi Shrishrimal.
View insider buying and selling activity for DexCom or view top insider-selling stocks.

Which major investors are buying DexCom stock?

DXCM stock was bought by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Sands Capital Management LLC, Clearbridge Investments LLC, Goldman Sachs Group Inc., Champlain Investment Partners LLC, Vanguard Group Inc., Twin Tree Management LP, and Aaron Wealth Advisors LLC.
View insider buying and selling activity for DexCom or or view top insider-buying stocks.

How do I buy shares of DexCom?

Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DexCom's stock price today?

One share of DXCM stock can currently be purchased for approximately $324.60.

How much money does DexCom make?

DexCom has a market capitalization of $31.85 billion and generates $2.45 billion in revenue each year. The medical device company earns $154.70 million in net income (profit) each year or $2.07 on an earnings per share basis.

How many employees does DexCom have?

DexCom employs 7,000 workers across the globe.

Does DexCom have any subsidiaries?

The following companies are subsidiares of DexCom: DexCapital LLC, DexCom (Canada) Inc., DexCom (UK) Distribution Ltd., DexCom (UK) Intermediate Holdings Ltd., DexCom (UK) Ltd., DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom Deutschland GmbH, DexCom International Ltd., DexCom Kommanditbolag, DexCom Operating Ltd., DexCom Philippines Inc, DexCom Suisse GmbH, Nintamed Handels GmbH, SweetSpot Diabetes Care Inc, The Glucose Program LLC, and TypeZero Technologies Inc.

When was DexCom founded?

DexCom was founded in 1999.

What is DexCom's official website?

The official website for DexCom is www.dexcom.com.

How can I contact DexCom?

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at (858) 200-0200, via email at [email protected], or via fax at 858-200-0201.